Aytu BioPharma shares surge 10.19% after-hours on EXXUA antidepressant launch progress and patent extension.

Aytu BioPharma surged 10.19% in after-hours trading following its Q1 fiscal 2026 earnings report and strategic updates. The company highlighted a $13.9 million net revenue, $2.0 million net income, and $32.6 million cash balance, while reaffirming its on-track December 2025 launch of EXXUA, a first-in-class antidepressant. Management emphasized EXXUA as a "game-changing" catalyst for growth in the $22 billion MDD market, with patent extensions and launch preparations progressing smoothly. The ADHD portfolio’s resilience, despite generic competition, further reinforced confidence. The stock’s rally aligned with positive sentiment around EXXUA’s commercial potential and operational efficiency, overshadowing a minor adjusted EBITDA loss. Key bullish factors included the patent extension, strong cash position, and detailed launch readiness, positioning Aytu for long-term growth.